Resources

Publish Date
Issue Briefs
Patent Quality in the United States

In September 2024, the nonprofit, nonpartisan Sunwater Institute published a study examining patent quality in the United States. The report found that...

Council for Innovation Promotion
Public Comments
C4IP Comments RE: Experimental Use Exception Request for Comments (PTO-C-2024-0023)
Council for Innovation Promotion
Letters
C4IP Letter to Senate HELP Committee RE: Hearing on The Medication Affordability and Patent Integrity Act
Council for Innovation Promotion
Letters
C4IP Letter to Senate Judiciary Committee RE: PERA
Council for Innovation Promotion
Letters
C4IP Letter to Senate Judiciary Committee RE: PERA, PREVAIL Act, and IDEA Act
Council for Innovation Promotion
Letters
C4IP Letter to Senate Judiciary Committee RE: IDEA Act
Council for Innovation Promotion
Public Comments
C4IP Comments RE: 2024 Guidance Update on Patent Subject Matter Eligibility, Including on Artificial Intelligence (PTO-P-2024-0026)
Council for Innovation Promotion
Reports
Overview of the USPTO Drug Exclusivity Report
Council for Innovation Promotion
Letters
C4IP Letter to Senate HELP Committee RE: The Medication Affordability and Patent Integrity Act
Council for Innovation Promotion
Public Comments
C4IP Comments RE: The Impact of the Proliferation of Artificial Intelligence on Prior Art, the Knowledge of a Person Having Ordinary Skill in the Art, and Determinations of Patentability Made in View of the Foregoing (PTO-P-2023-0044)
Council for Innovation Promotion
Letters
C4IP Letter to House Judiciary Committee RE: IP Litigation and the U.S. International Trade Commission
Council for Innovation Promotion
Public Comments
C4IP Comments RE: Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (PTO-P-2024-0003)
Council for Innovation Promotion
Resources:

Resources:

Patent Quality in the United States,

10/07/2024

Resources:

Resources:

C4IP Comments RE: Experimental Use Exception Request for Comments (PTO-C-2024-0023),

09/26/2024

Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: Hearing on The Medication Affordability and Patent Integrity Act,

09/25/2024

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: PERA,

09/24/2024

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: PERA, PREVAIL Act, and IDEA Act,

09/18/2024

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: IDEA Act,

09/17/2024

Resources:

Resources:

C4IP Comments RE: 2024 Guidance Update on Patent Subject Matter Eligibility, Including on Artificial Intelligence (PTO-P-2024-0026),

09/16/2024

Resources:

Resources:

Overview of the USPTO Drug Exclusivity Report,

09/12/2024

Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: The Medication Affordability and Patent Integrity Act,

08/26/2024

Resources:

Resources:

C4IP Comments RE: The Impact of the Proliferation of Artificial Intelligence on Prior Art, the Knowledge of a Person Having Ordinary Skill in the Art, and Determinations of Patentability Made in View of the Foregoing (PTO-P-2023-0044),

07/29/2024

Resources:

Resources:

C4IP Letter to House Judiciary Committee RE: IP Litigation and the U.S. International Trade Commission,

07/22/2024

Resources:

Resources:

C4IP Comments RE: Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (PTO-P-2024-0003),

07/09/2024

Scroll to Top